Indeed, SHARP (Haynes et al., 2014) and ALERT (Fellstrom et al., 2004) demonstrated no clear benefit of lipid lowering agents on renal disease progression, nor an association between lipid levels and progression of kidney disease (Rahman et al., 2014). This evidence concerns the gene SPEN and kidney disorder.